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Summary
Genetic loci for autosomal dominant pure hereditary
spastic paraplegia (ADPHSP) have beenmapped to chro-
mosomes 2p, 8q, 12q, 14q, and 15q. We undertook a
genomewide linkage screen of a large family with
ADPHSP, for which linkage at all previously identified
ADPHSP loci was excluded. Analysis of markers on
chromosome 19q gave a peak pairwise LOD score of
3.72 at D19S420, allowing assignment of a novel
ADPHSP locus (which we have termed “SPG12”) to this
region. Haplotype construction and analysis of recom-
bination events narrowed the SPG12 locus to a 16.1-
cM region between markers D19S868 and D19S902.
The hereditary spastic paraplegias (HSPs) are neurode-
generative disorders that are clinically characterized by
progressive lower-limb spasticity. They are convention-
ally classified as pure when spastic paraplegia exists in
isolation and as complicated when other major clinical
features are present. Autosomal dominant, autosomal
recessive, and X-linked–recessive inheritance patterns
have been described for both pure and complicated
forms of HSP (Harding 1984; Fink and Heiman-Patter-
son 1996; Kobayashi et al. 1996; Reid 1999).
There is locus heterogeneity within the autosomal
dominant, autosomal recessive, and X-linked reces-
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sive–HSP inheritance groups. This is most striking for
autosomal dominant pure HSP (ADPHSP), for which
five loci have been mapped—on chromosomes 2p (SPG4
[MIM 182601]; Hazan et al. 1994; Hentati et al. 1994),
8q (SPG8 [MIM 603563] Hedera et al. 1999b; Reid et
al. 1999b), 12q (SPG10 [MIM 604187] Reid et al.
1999a), 14q (SPG3 [MIM182600] Hazan et al. 1993),
and 15q (SPG6 [MIM 600363] Fink et al. 1995). The
existence of at least one additional ADPHSP locus was
strongly suggested by the exclusion of linkage at all five
of these loci (with LOD scores !2 throughout each
candidate region) in a large Welsh family, family 28
(Reid et al. 1999a, 1999b, 1999c).
Family 28 (fig. 1) was ascertained as part of a pre-
viously reported U.K.-wide clinical and genetic study of
ADPHSP (Reid et al. 1999c). After we obtained in-
formed consent, all available affected and apparently
unaffected family members were neurologically assessed
by a single physician (E.R.), by use of a standard pro-
tocol. Diagnostic criteria for ADPHSP were based on
those of Harding and have been described elsewhere
(Harding 1981, 1984; Reid et al. 1999c). In brief, sub-
jects were classified as being affected if they had lower-
limb hyperreflexia in addition to at least one of the fol-
lowing: progressive spastic-gait abnormality, bilateral
extensor-plantar reflex, and bilateral sustained (i.e., on
at least five beats) ankle or knee clonus. Subjects were
classified as being possibly affected if lower-limb hyper-
reflexia was present without other abnormal signs; and
they were classified as being normal if they had an en-
tirely normal neurological examination. Ethical ap-
proval for the study was granted by the Addenbrooke’s
Hospital ethical committee. In total, 18 family members
were clinically assessed. In addition, DNA samples were
available from an additional affected subject (II:4), who
was a deceased obligate gene carrier, and from two
spouses.
A genomewide screen, excluding the X chromosome
(because male-to-male transmission was present), was
Figure 1 Family tree of family 28 with ADPHSP, showing haplotypes for markers around the SPG12 region. The marker order, from top to bottom, is D19S414, D19S868, D19S416, D19S425,
D19S220, D19S223, D19S420, D19S918, D19S412, D19S545, and D19S902. For clarity, noncontributory haplotypes are represented by a uniform hatched shaded pattern. Recombination events in
affected individuals narrow the SPG12 critical region to an ∼16-cM region between D19S868 and D19S902 (see the Center for Medical Genetics, Marshfield Medical Research Foundation Web site).
For confidentiality, the sex of the subjects has been concealed. For affected patients, age at onset of symptoms is shown below the pedigree symbol; for clinically unaffected or possibly affected
subjects, age at examination is shown below the pedigree symbol. Blackened symbols denote affected individuals; ? = possibly affected; N = clinically normal;  = DNA available.
730 Am. J. Hum. Genet. 66:728–732, 2000
Table 1
LOD Scores for Family 28, with Markers from the SPG12 Region
MARKER
LOD SCORE AT v =
0 .05 .1 .2 .3 .4 .5
D19S414 2.186 1.276 1.359 1.183 .823 .376 .000
D19S868 3.722 .458 .129 .080 .085 .030 .000
D19S416 .997 .904 .810 .619 .423 .219 .000
D19S425 .273 .225 .180 .101 .043 .001 .000
D19S220 2.737 2.495 2.243 1.701 1.107 .473 .000
D19S223 2.992 2.712 2.421 1.802 1.135 .457 .000
D19S420 3.208 2.922 2.623 1.987 1.295 .565 .000
D19S918 3.201 2.920 2.625 2.000 1.318 .585 .000
D19S412 3.125 2.841 2.546 1.918 1.241 .536 .000
D19S545 1.911 1.817 1.679 1.318 .873 .385 .000
D19S902 2.107 1.440 1.475 1.226 .832 .380 .000
a Values were calculated on the basis of data on affected patients
and on two clinically normal subjects (ages 42 and 50 years,20 years
older than the oldest age at onset [i.e., 22 years] of disease in the
family) who were coded as unaffected.
commenced on DNA samples from the family, by use
of the ABI Linkage Mapping Set, version 2 (LMS2; PE
Biosystems), as described elsewhere (Reid et al. 1999a).
In addition to the LMS2 marker set, markers D19S868,
D19S416, D19S425, D19S223, D19S918, D19S412,
and D19S545 were used in genotyping. Primer sequences
for these additional markers are available from either
the Ge´ne´thon microsatellite-linkage map (Dib et al.
1996) or the Center for Medical Genetics, Marshfield
Medical Research Foundation Web site. PCR reaction
and thermocycling conditions were identical to those
used for the LMS2 marker set, except that the reactions
for D19S918 and D19S412 contained 10% dimethyl
sulfoxide and annealing temperatures were optimized
for each marker.
Pairwise linkage analysis was done by use of the
MLINK program of the FASTLINK, version 4.0P, pack-
age (Lathrop et al. 1985; Cottingham et al. 1993; Scha¨f-
fer et al. 1994), accessed via the Genetic Linkage User
Environment (GLUE) interface (UK Human Genome
Mapping Project Resource Centre). For linkage calcu-
lations, the gene frequency for ADPHSP was assumed
to be 104, and male and female recombination rates
were assumed to be equal. Maximum disease penetrance
was assumed to be 99%, as suggested elsewhere (Hazan
et al. 1994). Allele frequencies were assumed to be equal
for all markers—except D19S425, D19S220, D19S223,
D19S420, and D19S918, for which they were calculated
by genotyping a panel of unrelated U.K. subjects.
Clinical information on family 28 has been presented
elsewhere (Reid et al. 1999a, 1999b, 1999c, 1999d). All
affected subjects had a progressive spastic-gait abnor-
mality, in addition to lower-limb hyperreflexia, meeting
the Hereditary Spastic Paraplegia Working Group di-
agnostic criteria for being “definitely affected” (Fink and
Heiman-Patterson 1996), as well as our own diagnostic
criteria. The mean  SD age at onset of symptoms for
affected subjects in family 28 was (range6.9 6.2
5–22) years. One subject (III:3) who had a nonspastic-
gait abnormality with no signs of spastic paraplegia on
neurological examination was classified as possibly
affected.
In view of the age-dependent penetrance of ADPHSP,
pairwise LOD scores for genome-screening markers
were calculated by use of a conservative approach in
which only affected subjects and the two oldest unaf-
fected subjects (III:6 and III:11) were included in the
analysis. Both of these unaffected subjects were clinically
normal at ages 42 and 50 years, 20 years (and 3
SDs) older than the latest age at onset of disease symp-
toms in the family. All other family members were clas-
sified as “unknown” for purposes of the linkage analysis.
After carrying out linkage analysis for 124 markers, we
identified 2—D19S220 and D19S420, separated by 4.27
cM—that completely segregated with the disease. We
therefore analyzed additional markers from this region.
Pairwise LOD scores for these markers, derived by the
conservative linkage approach described earlier, are
shown in table 1. The peak pairwise LOD score was
3.208, at marker D19S420. We then repeated pairwise
linkage analysis at D19S420, assigning all clinically un-
affected subjects at 50% prior risk to liability classes
(derived from an age-at-onset-of-symptoms/signs curve
generated for the family), on the basis of the subject’s
age at examination. By using this analysis strategy, we
generated a pairwise LOD score of 3.720 for D19S420,
strongly supporting the assignment of a new ADPHSP
locus (which we have termed “SPG12”) to this region.
Haplotypes were constructed for markers from the re-
gion, and recombination events in affected individuals
place the disease locus within a 16.1-cM interval, flanked
by D19S868 and D19S902 (fig. 1). Previous cytogenetic
localization of D19S220 places this locus on chromo-
some 19q13.1 (see The Genome Database Web site).
The age at onset of symptoms in family 28 was early,
with a mean  SD of years. There may be6.9 6.2
locus-phenotype correlations in ADPHSP, with families
showing linkage to SPG3, SPG10, and SPG12 appar-
ently having an earlier age at onset of symptoms than
is seen in families showing linkage to SPG4, SPG6, or
SPG8. (Hazan et al. 1993; Hentati et al. 1994; Fink et
al. 1995; Gispert et al. 1995; Du¨rr et al. 1996; Haung
et al. 1997; Nielsen et al. 1998; Paternotte et al. 1998;
Hedera et al. 1999a, 1999b; Reid et al. 1999a, 1999b,
1999c; Rocco et al. 1999). Although these apparent cor-
relations need to be confirmed, they hint at locus-specific
differences in the molecular pathology of ADPHSP.
Genes involved in formation or maintenance of the
neuronal cytoskeleton or in myelination might be con-
sidered candidate genes for ADPHSP. Two such genes
Reports 731
have been mapped to the SPG12 region (see the
GeneMap’99 Web site). The cytoskeletal-associated pro-
tein 1, glycine motif, gene (CKAP1) contains a motif
that is highly conserved in certain cytoskeletal associated
proteins and that may mediate association with micro-
tubules (Watanabe et al. 1996). The myelin-associated
glycoprotein gene (MAG) may be involved in the process
of myelination (Barton et al. 1987). Both of these genes
are positional candidates for SPG12.
In summary, the data presented in this study identify
a sixth locus for ADPHSP. This is a further step in our
understanding of the full extent of genetic heterogeneity
of ADPHSP and will be of help in genetic counseling of
families with ADPHSP. Cloning of this and other HSP
genes will be vital in the understanding of the molecular
pathology of these interesting conditions.
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